NUCLEIN CLOSES $14M IN FUNDING LED BY TRINITY INVESTORS
- Trinity Investors
- Mar 30, 2021
- 1 min read
Updated: Mar 5
AUSTIN, Texas, March 25, 2021 /PRNewswire/ -- Nuclein, LLC has closed a $14 million Series B funding round. The financing helps Nuclein, a medical device company, to commercialize its novel, hand-held PCR platform designed as a disposable, all-in-one, self-test for infectious disease diagnosis.
Continue reading at the link below:
Trinity Investors is a private equity firm located in Southlake, Texas. If you are interested in learning more about our alternative investing opportunities, please contact a member of our Client Relations Team.
